The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
Background: Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to biological originator products, are expected to restrain drug costs in the biological m...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis
2022
|
| Online Access: | View Fulltext in Publisher |